Shandong Xinhua Pharmaceutical Shares Surge Over 7% After Approval for Self-Developed Benserazide Hydrochloride API

Stock News05-11

SHANDONG XINHUA (00719) rose more than 7% in the afternoon session. At the time of writing, the stock was up 6.76% to HK$6.63, with a turnover of HK$23.13 million.

The catalyst for the move was news that the company's self-developed Benserazide Hydrochloride active pharmaceutical ingredient (API) has officially received the "Chemical API Marketing Authorization Approval Notice" issued by the National Medical Products Administration, permitting its commercial production and sale.

This marks another significant achievement for Shandong Xinhua in the field of neurological disease treatment and represents a new breakthrough in the company's comprehensive drug supply chain for Parkinson's disease.

Benserazide Hydrochloride is a peripheral dopa decarboxylase inhibitor. As a core component of the classic Parkinson's disease treatment compound "Levodopa/Benserazide," it can significantly reduce the peripheral adverse effects of Levodopa and enhance therapeutic efficacy.

The finished dosage form containing this API is classified as a Category A drug in the "National Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance Drug List (2025)."

According to relevant statistical data, sales of Benserazide-related preparations in China's public medical institutions in 2025 were approximately RMB 1.4 billion.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1135254264?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-11 13:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135254264","market":"hk","top_or_hot":-1,"title":"Shandong Xinhua Pharmaceutical Shares Surge Over 7% After Approval for Self-Developed Benserazide Hydrochloride API","media":"Stock News","content":"<p>SHANDONG XINHUA (00719) rose more than 7% in the afternoon session. At the time of writing, the stock was up 6.76% to HK$6.63, with a turnover of HK$23.13 million.</p>\n<p>The catalyst for the move was news that the company's self-developed Benserazide Hydrochloride active pharmaceutical ingredient (API) has officially received the \"Chemical API Marketing Authorization Approval Notice\" issued by the National Medical Products Administration, permitting its commercial production and sale.</p>\n<p>This marks another significant achievement for Shandong Xinhua in the field of neurological disease treatment and represents a new breakthrough in the company's comprehensive drug supply chain for Parkinson's disease.</p>\n<p>Benserazide Hydrochloride is a peripheral dopa decarboxylase inhibitor. As a core component of the classic Parkinson's disease treatment compound \"Levodopa/Benserazide,\" it can significantly reduce the peripheral adverse effects of Levodopa and enhance therapeutic efficacy.</p>\n<p>The finished dosage form containing this API is classified as a Category A drug in the \"National Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance Drug List (2025).\"</p>\n<p>According to relevant statistical data, sales of Benserazide-related preparations in China's public medical institutions in 2025 were approximately RMB 1.4 billion.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shandong Xinhua Pharmaceutical Shares Surge Over 7% After Approval for Self-Developed Benserazide Hydrochloride API</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShandong Xinhua Pharmaceutical Shares Surge Over 7% After Approval for Self-Developed Benserazide Hydrochloride API\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-11 13:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SHANDONG XINHUA (00719) rose more than 7% in the afternoon session. At the time of writing, the stock was up 6.76% to HK$6.63, with a turnover of HK$23.13 million.</p>\n<p>The catalyst for the move was news that the company's self-developed Benserazide Hydrochloride active pharmaceutical ingredient (API) has officially received the \"Chemical API Marketing Authorization Approval Notice\" issued by the National Medical Products Administration, permitting its commercial production and sale.</p>\n<p>This marks another significant achievement for Shandong Xinhua in the field of neurological disease treatment and represents a new breakthrough in the company's comprehensive drug supply chain for Parkinson's disease.</p>\n<p>Benserazide Hydrochloride is a peripheral dopa decarboxylase inhibitor. As a core component of the classic Parkinson's disease treatment compound \"Levodopa/Benserazide,\" it can significantly reduce the peripheral adverse effects of Levodopa and enhance therapeutic efficacy.</p>\n<p>The finished dosage form containing this API is classified as a Category A drug in the \"National Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance Drug List (2025).\"</p>\n<p>According to relevant statistical data, sales of Benserazide-related preparations in China's public medical institutions in 2025 were approximately RMB 1.4 billion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VXUS","symbol_name":"国际股票ETF-Vanguard","start_time":0,"source_url":"","article_id":"1135254264","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135254264","pubTimestamp":1778478144,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"SHANDONG XINHUA (00719) rose more than 7% in the afternoon session. At the time of writing, the stock was up 6.76% to HK$6.63, with a turnover of HK$23.13 million. The catalyst for the move was news...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VXUS":"国际股票ETF-Vanguard","00719":"山东新华制药股份","BK4588":"碎股","IPOS":"Renaissance International IPO ETF","BK1515":"抗疫概念","BK4585":"ETF&股票定投概念","BK1191":"制药"},"translate_title":"自研盐酸苄丝肼原料药获批山东新华制药股价大涨超7%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"00719":1,"IPOS":1},"content_text":"SHANDONG XINHUA (00719) rose more than 7% in the afternoon session. At the time of writing, the stock was up 6.76% to HK$6.63, with a turnover of HK$23.13 million.\nThe catalyst for the move was news that the company's self-developed Benserazide Hydrochloride active pharmaceutical ingredient (API) has officially received the \"Chemical API Marketing Authorization Approval Notice\" issued by the National Medical Products Administration, permitting its commercial production and sale.\nThis marks another significant achievement for Shandong Xinhua in the field of neurological disease treatment and represents a new breakthrough in the company's comprehensive drug supply chain for Parkinson's disease.\nBenserazide Hydrochloride is a peripheral dopa decarboxylase inhibitor. As a core component of the classic Parkinson's disease treatment compound \"Levodopa/Benserazide,\" it can significantly reduce the peripheral adverse effects of Levodopa and enhance therapeutic efficacy.\nThe finished dosage form containing this API is classified as a Category A drug in the \"National Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance Drug List (2025).\"\nAccording to relevant statistical data, sales of Benserazide-related preparations in China's public medical institutions in 2025 were approximately RMB 1.4 billion.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1135254264","isCrawlerRequest":true}